443 results
Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: final 7-year results of the COMPARE-ABSORB trial
10 Mar 2026
This study provides the longest available follow-up for first-generation bioresorbable vascular scaffolds and fails to demonstrate any late clinical advantage after complete scaffold resorption.
Reviewer
Drug-coated balloon angioplasty vs up-front stenting for de novo CAD: 3-year follow-up of REC-CAGEFREE I trial
10 Mar 2026
The 3-year follow-up of the REC-CAGEFREE I trial demonstrated that a DCB-based strategy with rescue stenting was associated with a significantly higher rate of DOCE compared with contemporary DES implantation in patients with de novo, non-complex coronary artery disease.
Reviewer
Reviewer
Drug-eluting balloon in calcified lesions and complex lesions
28 Feb 2026 – From Euro4C Annual Meeting 2026
This session explores the application of drug-eluting balloons (DCB) in managing calcified and complex coronary lesions. Emphasis is placed on identifying appropriate lesions for a DCB-only strategy, the critical role of vessel preparation prior to drug delivery, and the long-term physiological assessment following treatment, supported by...
Complex coronary complications
11 Dec 2025 – From GulfPCR-GIM 2025
This session addresses complex coronary complications through a series of challenging cases including dextrocardia with acute STEMI, fragile coronary anatomy risks, left main complications, and stent-related issues. It provides critical insights into recognizing and managing unexpected procedural challenges to improve patient safety.
Challenging STEMI scenarios - Part 2
11 Dec 2025 – From GulfPCR-GIM 2025
This session presents complex STEMI cases that highlight the challenges of acute coronary syndrome management, including difficult arterial access, balancing reperfusion with embolization risks, and rare complications such as spontaneous coronary artery dissections. It emphasizes nuanced decision-making in high-stakes clinical scenarios.
Precision without a scaffold - When, why and how to use DCB in de novo lesions
11 Dec 2025 – From GulfPCR-GIM 2025
This session provided an in-depth examination of drug-coated balloon (DCB) use in de novo coronary lesions, emphasizing patient selection, lesion preparation, and procedural technique. Clinical evidence and real-world cases illustrated when and why DCBs represent a precise alternative to stenting, particularly in small vessels, high bleeding...
Imaging to the rescue
11 Dec 2025 – From GulfPCR-GIM 2025
This session highlighted the pivotal role of advanced intracoronary imaging techniques, particularly OCT, in complex case management such as in-stent restenosis and thrombus evaluation. Through real-world cases, it demonstrated how imaging complements physiology to guide therapeutic decisions, including the use of drug-coated balloons beyond native coronary...
Coronary Pot Pourri - 2
11 Dec 2025 – From GulfPCR-GIM 2025
This session presents a diverse range of complex coronary interventions, highlighting advanced techniques and strategies. Topics include the use of ECMO support for high-risk PCI and TAVI in cardiogenic shock, innovative approaches in left main interventions, challenging stent optimisation, and management of patients with combined severe...
Innovations in stentless coronary intervention: from DCB technologies to bioresorbable scaffolds
11 Dec 2025 – From GulfPCR-GIM 2025
This session delves into the evolving landscape of stentless coronary interventions, focusing on the structural diversity of Drug-Coated Balloons (DCB) and the promising future of bioresorbable scaffolds (BRS). It emphasizes the role of intracoronary imaging, particularly OCT, in optimizing these therapies. Attendees gain a comprehensive understanding...
Abstracts - Part 2
11 Dec 2025 – From GulfPCR-GIM 2025
This session compiles recent clinical abstracts addressing diverse topics in interventional cardiology. Highlights include the HYBRID-CTO approach from a prospective case series, the cardiovascular impact of empagliflozin in type 2 diabetes, off-label use of intravascular lithotripsy for resistant in-stent lesions, and experiences with non-hyperaemic pressure ratios...
